Investors Eye Erasca Class Action After $2.8 Billion Market Loss

The class action, covering the period between January 14, 2025, and April 26, 2026, alleges that Erasca executive leadership artificially inflated stock prices through deceptive public disclosures. The complaint highlights three primary points of contention: the use of flawed preclinical data to claim superiority over rival therapies like Revolution Medicines' RMC-6236, the suppression of critical intellectual property risks, and the downplaying of safety concerns that culminated in a trial-related fatality.

These misrepresentations allegedly collapsed in late April 2026, when the company was forced to disclose a legal challenge from Revolution Medicines alongside the grim clinical trial outcome. This sequence of events triggered a sharp sell-off, severely impacting portfolios held by individual and institutional investors. Reed Kathrein, the Hagens Berman partner overseeing the inquiry, stated that the firm is actively examining whether these omissions were intentional attempts to bolster the company's position in a high-stakes cancer treatment market.

Investors who incurred significant losses during the specified class period have until August 10, 2026, to move for appointment as lead plaintiff in the litigation. The firm is also encouraging whistleblowers with non-public information to come forward, citing potential SEC incentives for those who provide original evidence of corporate wrongdoing.